Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Mizuho Securities Reiterates Bullish Stance on Merrimack Pharmaceuticals (MACK) Into MM-398 PDUFA Date
August 11, 2015 7:46 AM EDTMizuho Securities analyst Peter Lawson reiterated an Outperform rating and $16 price target on Merrimack Pharmaceuticals (NASDAQ: MACK) heading into an October 24 PDUFA date for MM-398.
"The company remains one of our favorite biotech plays and we feel it is overlooked by investors, given... More
Merrimack Pharma (MACK) Tops Q2 EPS by 10c
August 10, 2015 5:06 PM EDTMerrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $36.6 million versus the consensus estimate of $17.57 million.
For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.
... More